This tracker provides data on global COVID-19 cases and deaths by country, region, and income-level. Additionally, the tracker reports current closure, economic, and health system policy responses to the COVID-19 pandemic globally. This tracker will be updated as new data are available.

This policy watch examines what the 2026 Midterm Election results and Democratic control of Congress might mean for global health.

AI is speeding up the search for new medicines. Can it make the discoveries themselves? Few people are better placed to answer than Dr. Elias Zerhouni. He ran the National Institutes of Health, then global R&D at Sanofi. He co-founded ModeX Therapeutics, which uses machine learning to design antibodies that don’t exist in nature, and he is now vice chairman and president of its parent company, OPKO Health. His test for AI: give it every piece of data available in the early 1950s, and it would not have found the double helix. The spark, he argues, is still human. Chip and Dr. Zerhouni dig into what AI is actually doing in drug development, how the FDA stacks up against regulators abroad, and what a slowdown in AI — and the erosion of American research — could mean for the next generation of cures.

This analysis finds that CMS’s proposed cut to Medicare reimbursement for 340B drugs, and accompanying increase for other outpatient services, will reduce revenues among safety-net hospitals while increasing revenues among for-profit hospitals.

This page displays an interactive map of the current status of state decisions on the Affordable Care Act's Medicaid expansion. Additional Medicaid expansion resources are listed (with links) below the map.

This tracker provides up-to-date information on countries with signed bilateral MOU global health agreements with the U.S.

The ACA Marketplace Open Enrollment season began November 1, bringing higher premiums, fewer insurer options in some states as more insurers exit the market, less access to health insurance subsidies, and less help finding coverage following federal actions to address broker fraud—among other changes to watch.

This brief provides an update on how the use of race in clinical decision-making tools has changed in recent years, as a growing number of medical specialties and institutions have moved away from race-based tools, and the implications of this change for racial health disparities.

This brief describes the transparency requirements that took effect in July 2026, uses T-MSIS data to assess the share of FFS spending and claims captured by certain reporting requirements, and discusses limitations of the new transparency requirements.

This dashboard focuses on KFF’s analysis of the role health care costs and other health policy issues played in voters’ decisions in the 2026 midterm elections, including in key Senate races. It examines the role of rising health costs on voters’ decisions, views on the Trump administration’s health care policies, and opinions on the government’s role in health care amid discussions of Medicare for All.

The analysis shows that plan level Medicare Advantage prescription drug availability varies widely across the country in 2027, with a modest reduction in the share of enrollees having more than 40 MA-PDs to choose from compared to 2026, and some major insurers exiting a much larger number of counties than they are entering.

This issue brief discusses the sub-regulatory guidance issued by USCIS to guide public charge determinations under the new rule and implications for immigrant families’ access to health coverage and care.

This brief discusses key Medicaid policy changes included in CMS budget neutrality guidance and identifies open questions about how the policy changes may be clarified and how they may affect states with existing 1115 waivers or states interested in applying for new ones.

This dashboard provides KFF’s analysis of the role abortion played in voters’ decisions in the 2026 midterm elections, with a focus on four states with abortion-related ballot measures: Idaho, Missouri, Nevada, and Virginia. It examines support for each of the measures across groups, including additional questions in Missouri, where voters were asked to weigh in on a ballot measure that combined questions of abortion access with restrictions on gender-affirming care.

This State and Federal Reproductive Rights Litigation tracker aggregates information about ongoing litigation regarding abortion bans and restrictions, FDA approval of Mifepristone (an abortion pill) and other federal regulations.